Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lawrence

Showing results (511-520 of 534) with videos related to

Pageof 54
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.
Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Plos Pathogens|June 17, 2022
A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infectionScott P Lawrence, Samra E Elser, Workineh Torben, et al.
Pageof 54

Showing results (511-520 of 534) with videos related to

Sort By:
Pageof 54
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.
Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Plos Pathogens|June 17, 2022
A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infectionScott P Lawrence, Samra E Elser, Workineh Torben, et al.
Pageof 54